Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q− syndrome.

Lenalidomide (Revlimid, Celgene) is an immunomodulatory agent with both erythropoetic and cytogenetic remitting activity in patients with primary myelodysplastic syndrome (MDS) associated with ...

Current data from real-world settings indicate treatment initiation with lenalidomide and disease monitoring in patients with myelodysplastic syndrome with del(5q) (MDS-del[5q]) greatly vary, ...

Celgene Corporation (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) granted approval of REVLIMID (lenalidomide) which is indicated for the treatment of patients with ...

Summit, N.J., June 29 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...

Celgene International Sàrl (NASDAQ: CELG) announced that, following discussions with the European Medicines Agency (EMEA) and the EMEA’s Committee for Medicinal Products for Human use (CHMP), it has ...

Revlimid is showing promise for patients with low-risk MDS, according to the results of a recent study. Nearly 40 percent of patients with low intermediate-1 risk myelodysplastic syndrome (MDS) who ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has ...